$TNXP
The big question is "but why share price kept declining?"
The answer is "because that's how big boys accumulate shares before they 'pump'"
It's not whether but when #10bagger!
$TNXP
Millennium Management LLC filed 13G today, increasing shares from 219,673 on 13F filing for the 1st Q to 890,366 shares on today's 13G filing, about 5.6%.
Institutions and hedge funds steadily increasing their holding, I guess this process would be accelerated.
#10bagger
The PCR positivity map is out and it's another poor week for reporting, with data delays owing to the late May Bank Holiday mentioned on DASH.
Adjusted national positivity is 2.89%.
https://t.co/1phcyp7jth
1/4
Covid infection levels in England have fallen to their lowest recorded level so far. We have reduced the Covid risk level, for the first time, to Low. 1 in every 2154 people in England are now infected.
A thread 🧵
https://t.co/Qp4sgHVa4i
@Arhdan9@SethLederman Whole bunch of panic on a trading platform yesterday, investors who expect a quick buck, most sold at 10, now it’s climbing again. None of them understood how good the sales are, what insurance coverage expansion means, or $TNXP pipeline or its trials to expand Tonmya. Fools.
$TNXP sales growth is excellent, insurance coverage is expanding now, more insider buying during last 24 hours.
Massively undervalued in the market, expect a strong bounce, the sales can’t be ignored for long $TNXP Tonmya blockbuster drug in the making
$TNXP sales growth is excellent, insurance coverage is expanding now, more insider buying during last 24 hours.
Massively undervalued in the market, expect a strong bounce, the sales can’t be ignored for long $TNXP Tonmya blockbuster drug in the making
@tratuein Market hasn’t reacted yet, it usually wants to see at least two full quarters of sales, that hadn’t happened yet. But it will eventually and ex US deals will happen, just got to be patient
@PasserLabs Confident it will, Tonmya will be established as a core drug in that limited field, ex US roll out will happen too, just takes time as all drugs do, it’s funny seeing those shorting it panic now it has become a commercial company with a great pipeline in development too
$TNXP upcoming catalysts:
- phase 2 results for Tonmya expansion into depression & anxiety treatment
- FDA meeting to agree on Lyme disease phase 2 clinical trials (Q3)
- phase 2 for kidney transplant anti rejection therapy
- Q2,Q3,Q4 Tonmya sales growth & ex US partner news
$TNXP is shorted heavily, as Tonmya sales hit over $1 million per week + insurance coverage expands, it is primed for a short squeeze, currently $12-13, was >$60 on FDA approval, we will see that again easily. Remember to HOLD, that’s how you make the short squeeze happen $TNXP